Responsiveness of the motor function measure in neuromuscular diseases
Middle Aged; Male; Aged; Mobility Limitation; Young Adult; Child; Humans; Adult; Prospective Studies; Adolescent; Perception; Female; Disability Evaluation; Motor Skills; Physical Therapy Modalities; Muscular Dystrophy Duchenne/physiopathology/rehabilitation; Neuromuscular Diseases/physiopathology/rehabilitation; tone and motor problems; SMA1; Q3 conditions; tool development; scale development; motor function measure; MFM
OBJECTIVES: To study the responsiveness (sensitivity to change) of the Motor Function Measure (MFM) in detecting change in neuromuscular disease patients with the intent of using this measure in future clinical trials. DESIGN: Prospective cohort observational study. SETTING: Inpatient and outpatient facilities for follow-up and treatment of neuromuscular diseases. PARTICIPANTS: Patients (N=152) with various neuromuscular diseases aged 6 to 60 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE(S): We used the MFM total score and its 3 subscores on 2 measurements grossly 1 year apart. The physicians and the patients (or proxy) were asked to provide their perceived change in functional status since the first MFM. These changes were expressed in 3 outcomes: deterioration, stability, or improvement. RESULTS: The overall 12-month-standardized mean change of the total score mean +/- SD annual total score change was -2.4+/-5.5 points (P<.001), with patients with Duchenne muscular dystrophy (DMD) presenting the most significant change (-5.8+/-6.3, P<.001). The change in patients reporting deterioration (34%) was significantly larger than that of those reporting stability (47%) or improvement (10%) (-4.4+/-6.4 vs -2.0+/-5.6 and +0.9+/-4.4 points, respectively, P<.01). The 12-month-standardized total score changes were significantly greater in physician-rated deteriorated (49%) versus stable patients (51%), with mean differences in scores being -5.3+/-7.6 and -1.2+/-5.3, respectively (P<.001). CONCLUSIONS: The MFM showed a good responsiveness, especially in patients with DMD and agreements with patients' and physicians' perceived change. Confirming this responsiveness requires larger age groups of patients with DMD and other neuromuscular diseases as well as disease-specific interexamination delays.
Vuillerot C; Payan C; Girardot F; Fermanian J; Iwaz J; Berard C; Ecochard R
Archives of Physical Medicine and Rehabilitation
2012
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.apmr.2012.05.025" target="_blank" rel="noreferrer noopener">10.1016/j.apmr.2012.05.025</a>
Motor Function Measure: Validation of a Short Form for Young Children With Neuromuscular Diseases
reliability; Rehabilitation; scale; spinal muscular-atrophy; ambulation; Disability evaluation; dystrophy; Neuromuscular diseases; outcome measure; sma-iii patients; Sport Sciences; SMA1; tool development; scale development
Objective: To validate a useful version of the Motor Function Measure (MFM) in children with neuromuscular diseases aged <7 years old. Design: Two prospective cohort studies that documented the MFM completion of children aged between 2 and 7 years old. Setting: French-speaking rehabilitation departments from France, Belgium, and Switzerland. Participants: Healthy children (n=194) and children with a neuromuscular disease (n=88). Interventions: Patients were rated by the MFM either once or twice by trained medical professionals, with a delay between the 2 MFMs ranging between 8 and 30 days. Main Outcome Measure: Intra- and interrater reliability of the MFM. Results: The subtests making up the MFM-32, a scale monitoring severity and progression of motor function in patients with a neuromuscular disease in 3 functional domains, were carried out in healthy children aged 2 to 7 years. Twenty items of the MFM-32 were successfully completed by these children and were used to constitute the MFM-20. Principal component analysis of the MFM-20 confirmed the 3 functional domains. Inter- and intrarater reliability of the 3 subscores and total score were high (intraclass correlation coefficient >.90), and discriminant validity was good. Conclusions: The MFM-20 can be used as an outcome measure for assessment of motor function in young children with neuromuscular disease. (C) 2013 by the American Congress of Rehabilitation Medicine
de Lattre C; Payan C; Vuillerot C; Rippert P; de Castro D; Berard C; Poirot I;MFM Study Group
Archives of Physical Medicine and Rehabilitation
2013
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.apmr.2013.04.001" target="_blank" rel="noreferrer noopener">10.1016/j.apmr.2013.04.001</a>